DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidVSDPDAleft-to-right shuntEisenmengeradult congenital heart disease

Ventricular septal defect and patent ductus arteriosus

Essential points for quick revision.

!
Escalate

New cyanosis, haemoptysis, syncope, infective-endocarditis features or decompensated heart failure in an adult with VSD/PDA needs urgent ACHD assessment; do not arrange routine closure when Eisenmenger physiology is possible.

Synopsis

Recognise residual or unrepaired VSD and PDA in adults, identify closure indications and avoid intervention after irreversible pulmonary vascular disease.

  • A small restrictive VSD can produce a loud pansystolic murmur despite a small shunt.
  • A large VSD causes left-heart volume loading and, if uncorrected, pulmonary vascular disease and shunt reversal.
  • PDA classically causes a continuous left infraclavicular murmur, bounding pulses and wide pulse pressure when the shunt is substantial.

Key red flags

Eisenmenger conversion

Cyanosis, clubbing, erythrocytosis, haemoptysis or syncope signals advanced pulmonary vascular disease and makes closure hazardous.

Investigation priorities

01
Transthoracic echocardiographyFirst step

Define defect/duct, direction and velocity of flow, chamber size, valves and estimated pulmonary pressure.

Management branches

FirstNew or residual VSD/PDA

Characteristic murmur, unexplained chamber dilatation, cyanosis or known childhood lesion.

  1. Obtain prior operative/catheter records and perform examination including upper- and lower-limb saturation.
  2. Use expert TTE to define lesion, shunt, ventricular effects, valves and pulmonary pressure.
Open full textbook Answer 2 questionsCardiology check
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom